Constitutive activation of transcription factor NFκB as a possible marker of sensitivity of neoplastic cells to anthracyclines

Acta Poloniae Pharmaceutica - Drug Research

Volumn 62, Issue 1, 2005, Pages 17-23

  Gruber, Beata M ^a   Anuszewska, Elzbieta L ^a   Bubko, Irena ^a   Kasprzycka Guttman, Teresa ^a   Misiewicz, Irena ^a   Skupińska, Katarzyna ^a   Priebe, Waldemar ^b   Fokt, Izabela ^b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anthracyclines; Constitutive activation; Cytotoxicity; NF B

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR REL; UNCLASSIFIED DRUG; WP 903; ANTHRACYCLINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR MARKER;

APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL; HUMAN; HUMAN CELL; TUMOR CELL; BIOTRANSFORMATION; CELL NUCLEUS; DRUG EFFECT; METABOLISM; NEOPLASM;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CELL NUCLEUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICROSCOPY, CONFOCAL; NEOPLASMS; NF-KAPPA B; TETRAZOLIUM SALTS; THIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 24944453211     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bharti A.C., Aggarvval B.B.: Biochem. Pharmacol. 64, 883 (2002).
2. Garg A., Aggarwal B.B.: Leukemia 16, 1053 (2002).
3. Andriollo M., Favier A., Guiraud P.: Arch. Biochem. Biophys. 413, 75 (2003).
4. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B.: Biochem. Pharmacol. 67, 353 (2004).
5. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.-L., Milano G., Peyron J.-F.: Cancer Res. 61, 7785 (2001).
6. Huang S., DeGuzman A., Bucana C.D., Fidler I.J.: Clin. Cancer Res. 6, 2573 (2000).
7. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V.: J. Cell Sci. 115, 141 (2002).
8. Bureau F., Vanderplasschen A., Jaspar F., Minner F., Pastoret P.-P., Merville M.-P., Bours V., Lekeux P.: Blood 99 (10), 3683 (2002).
9. Shishodia S., Aggarwal B.B.: J. Biochem. Mol. Biol. 35 (1), 28 (2002).
10. Kordes U., Krappmann D., Heissmeyer V., Ludwig W.D., Scheidereit C.: Leukemia 14, 399 (2000).
11. McNulty S.E., Tohidian N.B., Meyskens F.L. Jr.: Pigment Cell Res. 14 (6), 456 (2001).
12. Oya M., Ohtsubo M., Takyanagi A., Tachibana M., Shimizu N., Murai M.: Oncogene 20 (29), 3888 (2001).
13. Shattuck-Brandt R.L., Richmond A.: Cancer Res. 57, 3032 (1997).
14. Anuszewska E.L., Gruber B.M., Koziorowska Jadwiga H.: Biochem. Pharmacol. 54, 597 (1997).
15. Gruber B.M., Anuszewska E.L.: Toxicology in vitro 16, 663 (2002).
16. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., Schafer H.: Oncogene 21 (16), 2611 (2002).
17. McNulty S.E., del Rosario R., Cen D., Meyskens F.L. Jr., Yang S.: Pigment Cell Res. 17 (2), 173 (2004).
18. Bours V., Dejardin E., Goujon-Letawe F., Merville M.-P., Castronovo V.: Biochem. Pharmacol. 47 (1), 145 (1994).
19. Chiao P.J., Na R., Niu J., Sclabas G. M., Dong Q., Curley S. A.: Cancer 95 (8), 1696 (2002).